Solar energy has always played a special role among renewable energies. In contrast to energy generation through wind energy, a single household could make an individual contribution to social change towards sustainable energy generation by simply switching to photovoltaic systems. Accordingly, this was also subsidized by the state in many cases.
For the manufacturers of solar systems and modules, the future is currently solid to positive. Both SolarEdge Technologies Inc. and Sunrun Inc. were able to exceed analysts' expectations with their respective Q2 results: SolarEdge showed a profit of $ 1.28 / share compared to a market expectation of $ 1.11 / share and Sunrun was able to increase sales to $ 401m, with the Market was expecting $ 366.6m, prompting Sunrun to raise its Growth Guidance to 30% for the current fiscal year. In both cases, the analyst community took good note of this: Buy recommendations for both values currently predominate in the market.
Also exciting is the prospect of First Solar Inc., with $ 10 billion from an industry giant. After a change of strategy towards a pure focus on the production of photovoltaic modules, the aim is now to increase production of these significantly by massively expanding factories in the USA and India. This could result in a doubling of production capacities.
18.5% p.a. (USD) / 17.5% p.a. (CHF) Barrier Reverse Convertible on First Solar, Sunrun, SolarEdge Tech*
Valors 58 533 119 (USD) / 58 533 120 (CHF)
The manufacturers of polysilicon, an important raw material for photovoltaic production, could also benefit from this. Wacker Chemie, with an annual production of more than 60,000 t, is a key supplier here.
9.5% p.a. Barrier Reverse Convertible on Wacker Chemie*
*indicative
Disclaimer
This communication is for marketing purposes. It is neither an offer nor an invitation to submit an offer, to purchase or to subscribe to securities and does not constitute investment advice. You should consult your advisors before making an investment decision.
Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, financial condition, development or performance of the issuer to be materially different from any future results, financial condition, development or performance expressed or implied by such statements.
The present document has not been drawn up by the research department as defined in the rules of the “Directives on the Independence of Financial Research” published by the Swiss Bankers Association, hence these rules do not apply to this document.
If securities are mentioned in the communication, the base prospectus, the final terms and any key information document may be obtained free of charge from Zürcher Kantonalbank, Bahnhofstrasse 9, 8001 Zurich, VRIS, and from www.zkb.ch/finanzinformationen.
ZKB Barrier Reverse Convertible mit bedingtem Coupon on worst of Salesforce.com Inc/NVIDIA Corp/Supe... 132913957 / CH1329139575 |
ZKB Autocallable Barrier Reverse Convertible on worst of Biogen Inc/BioNTech SE/Moderna Inc 132913422 / CH1329134220 |
ZKB Reverse Convertible auf Moderna Inc 135805537 / CH1358055379 |
22.09% ZKB Reverse Convertible, 16.01.2025 on worst of NVDA UW/TSLA UW/MRNA UW NVIDIA Corp/Tesla Inc... 130398418 / CH1303984186 |
11.17% ZKB Reverse Convertible, 03.03.2025 on worst of QCOM UW/AAL UW/MRNA UW Qualcomm Inc/American ... 135805027 / CH1358050271 |